Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Therapeutic decisions for glaucoma patients weigh benefits
Chicago-IOP control remains the basis for primary treatment of glaucoma, but there have been some recent changes in the medical and surgical arenas. Now, a prostaglandin analogue is often used instead of a beta-blocker as first-line therapy, selective laser trabeculoplasty (SLT) has emerged as another option for primary laser surgery, and meanwhile, there is growing patient interest in complementary medicine alternatives.
Related Videos
Related Content
